The Human Variable 

The Cultural Gendered Patriarchy Index (CGPI), developed by CYNAERA (2025), is the first cross-national system designed to quantify the effect of patriarchy on male diagnostic rates. By integrating data from 180 countries—including global gender indices, masculinity scales, health-seeking behavior datasets, and IACC prevalence studies—we reveal that millions of men are statistically invisible.

The CDF-Peds-ME/CFS™, developed by CYNAERA, is the first child-adapted Composite Diagnostic Fingerprint designed for school, home, and clinical settings. Built on CYNAERA’s validated CDF-ME framework, it integrates multi-system biomarkers, digital phenotyping, and school-based records into a practical, developmentally appropriate diagnostic solution.

CYNAERA’s PHAROS™ + REWIRE™ framework introduces a longitudinal, multi-pathway diagnostic system. By tracking cytokine rhythms over days, mapping vagal-histaminergic amplification, and integrating viral reactivation profiles, PHAROS™ + REWIRE™ replaces linear models with terrain-aware detection. This paper expands on the biological foundations of this model, critiques failed legacy approaches, and outlines a replicable path to mechanism-specific, real-world diagnostics.

Clinical trials for ME/CFS have consistently failed not because therapies were inherently ineffective, but because the system was never built for conditions like ME/CFS and related IACCs. FDA gold-standard trial design assumes predictable progression, uniform subtypes, and tolerance for interventions — none of which apply to ME/CFS The CYNAERA Thesis asserts that repurposed drugs can work for ME/CFS if trials account for post-exertional malaise (PEM),(MCAS), and POTS

The Va-IRI™ (Vaccination Immune Readiness Index) provides a structured 0–100 readiness score derived from common labs, symptom baselines, and patient function. Built on the STAIR Stable Method™ (Stabilization, Tolerance, And Immune Readiness), Va-IRI™ adapts low-and-slow principles pioneered by patients and refined through collaboration with leading researchers.

Using CYNAERA’s recalibrated US-CCUC™ prevalence models, which place the U.S. burden between 8.7 million (conservative) and 21.5 million (realistic), the annual economic impact rises to $243–817 billion.